Cargando…
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701068/ https://www.ncbi.nlm.nih.gov/pubmed/33108585 http://dx.doi.org/10.1007/s11523-020-00762-6 |
| _version_ | 1783616415857639424 |
|---|---|
| author | Ramanathan, Ramesh K. Von Hoff, Daniel D. Eskens, Ferry Blumenschein, George Richards, Donald Genvresse, Isabelle Reschke, Susanne Granvil, Camille Skubala, Adam Peña, Carol Mross, Klaus |
| author_facet | Ramanathan, Ramesh K. Von Hoff, Daniel D. Eskens, Ferry Blumenschein, George Richards, Donald Genvresse, Isabelle Reschke, Susanne Granvil, Camille Skubala, Adam Peña, Carol Mross, Klaus |
| author_sort | Ramanathan, Ramesh K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7701068 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77010682020-12-03 Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer Ramanathan, Ramesh K. Von Hoff, Daniel D. Eskens, Ferry Blumenschein, George Richards, Donald Genvresse, Isabelle Reschke, Susanne Granvil, Camille Skubala, Adam Peña, Carol Mross, Klaus Target Oncol Correction Springer International Publishing 2020-10-27 2020 /pmc/articles/PMC7701068/ /pubmed/33108585 http://dx.doi.org/10.1007/s11523-020-00762-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Correction Ramanathan, Ramesh K. Von Hoff, Daniel D. Eskens, Ferry Blumenschein, George Richards, Donald Genvresse, Isabelle Reschke, Susanne Granvil, Camille Skubala, Adam Peña, Carol Mross, Klaus Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer |
| title | Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer |
| title_full | Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer |
| title_fullStr | Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer |
| title_full_unstemmed | Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer |
| title_short | Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer |
| title_sort | correction to: phase ib trial of the pi3k inhibitor copanlisib combined with the allosteric mek inhibitor refametinib in patients with advanced cancer |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701068/ https://www.ncbi.nlm.nih.gov/pubmed/33108585 http://dx.doi.org/10.1007/s11523-020-00762-6 |
| work_keys_str_mv | AT ramanathanrameshk correctiontophaseibtrialofthepi3kinhibitorcopanlisibcombinedwiththeallostericmekinhibitorrefametinibinpatientswithadvancedcancer AT vonhoffdanield correctiontophaseibtrialofthepi3kinhibitorcopanlisibcombinedwiththeallostericmekinhibitorrefametinibinpatientswithadvancedcancer AT eskensferry correctiontophaseibtrialofthepi3kinhibitorcopanlisibcombinedwiththeallostericmekinhibitorrefametinibinpatientswithadvancedcancer AT blumenscheingeorge correctiontophaseibtrialofthepi3kinhibitorcopanlisibcombinedwiththeallostericmekinhibitorrefametinibinpatientswithadvancedcancer AT richardsdonald correctiontophaseibtrialofthepi3kinhibitorcopanlisibcombinedwiththeallostericmekinhibitorrefametinibinpatientswithadvancedcancer AT genvresseisabelle correctiontophaseibtrialofthepi3kinhibitorcopanlisibcombinedwiththeallostericmekinhibitorrefametinibinpatientswithadvancedcancer AT reschkesusanne correctiontophaseibtrialofthepi3kinhibitorcopanlisibcombinedwiththeallostericmekinhibitorrefametinibinpatientswithadvancedcancer AT granvilcamille correctiontophaseibtrialofthepi3kinhibitorcopanlisibcombinedwiththeallostericmekinhibitorrefametinibinpatientswithadvancedcancer AT skubalaadam correctiontophaseibtrialofthepi3kinhibitorcopanlisibcombinedwiththeallostericmekinhibitorrefametinibinpatientswithadvancedcancer AT penacarol correctiontophaseibtrialofthepi3kinhibitorcopanlisibcombinedwiththeallostericmekinhibitorrefametinibinpatientswithadvancedcancer AT mrossklaus correctiontophaseibtrialofthepi3kinhibitorcopanlisibcombinedwiththeallostericmekinhibitorrefametinibinpatientswithadvancedcancer |